myChart login

Current & Featured Studies

Decrease (-) Restore Default Increase (+)

Current & Featured Studies

Current CRI Studies

The WakeMed Clinical Research Institute is currently participating in clinical studies in the following areas.

  • Type 2 Diabetes Mellitus
  • Respiratory Syncytial Virus
  • Cardiovascular Research Technologies
  • Coronary Artery Disease
  • Type 2 Diabetes Mellitus in Pediatrics
  • Acute Bacterial Skin and Skin Structure Infection
  • Type I Diabetes
  • Jaundice in Neonates
  • Venous Thrombo-Embolism
  • Heart Failure with left bunch branch block
  • Cardiovascular Research Technologies
  • Coronary Artery Disease
  • Infection Prevention
  • Preeclampsia
  • Induction of Labor
  • Hepititis C Virus
  • Cytomegalovirus in Pregnancy
  • Pre-term Delivery
  • Hypothyroidism in Pregnancy
  • Gestational Diabetes
  • Electronic Fetal Monitoring
  • Complicated Intra-abdominal Infections
  • Retinopathy of Prematurity Prevention
  • High Risk Pre-Term Infants
  • Necrotizing Enterocolitis Prevention
  • At Risk for Type I Diabetes
  • Human Growth Hormone
  • Dislipidemia
  • Probiotic in Low Birth Weight Infants

Contact CRI for more information on clinical research studies.

Featured CRI Studies

We are currently recruiting study participants for the following studies:

WakeMed Pediatric Endocrinology is involved in many different types of diabetes and research projects. Please read below for information on current research opportunities available to you and your family. To learn more about these opportunities, please contact the Pediatric Endocrinology Research Coordinator at 919-350-5882.

Type 1 Diabetes: TrialNet

Do you have a family member with Type 1 Diabetes?

If the answer is “yes”, then you and your family may have a unFique opportunity to join in the fight against diabetes. Researchers from The University of Florida and WakeMed Pediatric Endocrinology, in collaboration with the National Institutes of Health and Clinical Centers across the country, are seeking a better understanding of how Type 1 diabetes develops. TrialNet researchers are also searching for ways to both prevent and quickly intervene medically in those newly diagnosed with the disease.

For Trialnet’s Natural History Study, researchers are seeking to test family members of people with Type 1 diabetes to determine if these family members show signs of developing the disease.

The clinic is also engaged in other TrialNet sponsored studies.

To learn more about TrialNet, visit or contact our research coordinator at 919-350-5882.


Type 2 Diabetes: WELKid DM Study

With the growing number of children and adolescents developing Type 2 diabetes, there is a need for alternative treatment options. Welchol (colesevelam) is a medication that is currently FDA approved to treat high cholesterol in both children and adults. Recently it was found to improve blood sugars in adults with Type 2 diabetes, and has been approved to treat Type 2 diabetes in adults. The WELKid DM study is looking at the safety and effectiveness of Welchol (colesevelam) as a treatment for children and adolescents with Type 2 diabetes.

To learn more about the WELKid DM study, contact our research coordinator at 919-350-5882.


Growth Hormone: ANSWER

Is your child currently on Norditropin?

If the answer is “yes”, your child may qualify to participate in this long-term study. ANSWER is a multi-national database that anonymously collects patient information that will provide data about growth hormone safety, efficacy, dosing requirements, and secondary benefits. This study is only for patients currently on Norditropin (your child can participate even if they have previously been on a different brand of growth hormone).

To learn more about ANSWER, contact our research coordinator at 919-350-5882.


Newly Diagnosed Type 1 Diabetecs: Grifols Alpha 1-PI Infusion Study

The purpose of this study is to evaluate the safety and efficacy of a medication, Alpha 1-PI, that has shown to prevent beta cell destruction in the pancreas and slow the progress of Type 1 diabetes. Qualified participants should be between 12 and 35 years of age and have been diagnosed with Type 1 diabetes within the last 3 months. Other inclusion and exclusion criteria may apply.

For more information, contact our research coordinator at 919-350-5882.







© WakeMed Health & Hospitals, Raleigh, NC  |  919.350.8000